Combined histopathological risk score using TP53 protein expression, CD8+ T cell density and intratumoral budding is an independent predictor of neoadjuvant therapy response in rectal adenocarcinoma. Issue 5 (3rd September 2021)

• Record Type: Journal Article
• Authors: Chen, Wei; Farchoukh, Lama; Seigh, Lindsey; Hartman, Douglas J; Pai, Reetesh K
• Is Part Of: Histopathology. Volume 79:Issue 5(2022)
• Page Start: 826
• Page End: 835
• Publication Date: 2021-09-03
• Subjects: CD8+ T cell density -- intratumoral budding -- neoadjuvant therapy response -- rectal adenocarcinoma -- TP53; Histology, Pathological -- Periodicals; 611.018
• DOI: 10.1111/his.14430
• Languages: English
• ISSNs: 0309-0167

Abstract

Abstract : Aims: Neoadjuvant therapy is the recommended treatment for locally advanced rectal adenocarcinoma; however, there remains significant variability in response to therapy. Tumour protein 53 (TP53) has been associated with therapy response and prognosis with conflicting data. Recently, we demonstrated that immune cell density and intratumoral budding (ITB) are predictive factors in rectal cancer. We investigated the predictive value of TP53 immunohistochemistry with CD8 + T cell density and ITB on pretreatment biopsies of rectal adenocarcinoma for response to neoadjuvant therapy. Methods and results: Pretreatment biopsies of rectal adenocarcinoma from 117 patients with neoadjuvant therapy were analysed for TP53 expression by immunohistochemistry, ITB, CD8 + T cell density and mismatch repair protein (MMR) status. Most rectal adenocarcinomas displayed aberrant TP53 expression (86 of 117, 74%). Compared to wild‐type TP53, aberrant TP53 expression was associated with proficient MMR status ( P = 0.003) and low CD8 + T cell density ( P = 0.001). Aberrant TP53 was significantly associated with a partial to poor response to neoadjuvant therapy [odds ratio (OR) = 2.42, 95% confidence interval (CI) = 1.04–5.62, P = 0.04]. A combined histopathological risk score (HRS) was created using CD8 + T cell density, ITB and TP53 expression. Patients were separated into low (none to one factor) and high (two to three factors) HRS categories. In the multivariable model, patients with a high HRS were 3.25‐fold more likely to have a partial or poor response to neoadjuvant therapy (95% CI = 1.48–7.11, P = 0.003). Conclusions: Our study demonstrates that aberrant TP53 expression, high ITB and low CD8 + T cell density in pretreatment biopsies can help predict response to neoadjuvant therapy. These biomarkers may be helpful in identifying patients at risk for therapy resistance. Abstract :